National Medical Products Administration. Recaticimab: NMPA Approval No. S20250002. 2025.

Hengrui. The world's first ultra-long-acting PCSK9 monoclonal antibody! Hengrui's innovative lipid-lowering drug Relcarcimab was approved for marketing [Google translation] [media release]. 13 Jan 2025. https://www.hengrui.com/.

Schonck WAM, Stroes ESG, Hovingh GK, et al. Long-term efficacy and tolerability of PCSK9 targeted therapy: a review of the literature. Drugs. 2024;84:165–78.

CAS  PubMed  PubMed Central  Google Scholar 

Safarova M, Bimal T, Soffer DE, et al. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond. Am J Prevent Cardiol. 2024;19: 100701.

Google Scholar 

Coppinger C, Movahed MR, Azemawah V, et al. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022. https://doi.org/10.1177/10742484221100107

Zhao SP, Yu BL, Peng DQ, et al. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial. Atherosclerosis. 2014;233(2):707–12.

CAS  PubMed  Google Scholar 

Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934.

CAS  PubMed  PubMed Central  Google Scholar 

Savage P, Cox B, Shahmohammadi M, et al. Advances in Clinical Cardiology 2023: a summary of key clinical trials. Adv Ther. 2024;41(7):2606–34.

PubMed  PubMed Central  Google Scholar 

Hengrui. Hengrui Medicine's innovative lipid-lowering drug, anti-PCSK9 monoclonal antibody recaticimab, has been accepted for marketing approval [Google translation] [media release]. 21 Jun 2023. https://www.hengrui.com/.

Hengrui. Recaticimab for injection: Chinese prescribing information. 2025.

Xu M, Zhu X, Wu J, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022;20(13):1–13.

CAS  Google Scholar 

Xu M, Wang Z, Zhang Y, et al. Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipidemia: the phase 3 REMAIN-1 randomized trial. J Am Coll Cardiol. 2024;84(20):2026–36.

CAS  PubMed  Google Scholar 

Gupta K, Hinkamp C, Andrews T, et al. Highlights of cardiovascular disease prevention studies presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023;25(12):965–78.

CAS  PubMed  Google Scholar 

Sun Y, Lv Q, Guo Y, et al. Recaticimab as add-on therapy to statins for nonfamilial hypercholesterolemia: the randomized, phase 3 REMAIN-2 trial. J Am Coll Cardiol. 2024;84(20):2037–47.

CAS  PubMed  Google Scholar 

Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514–24.

CAS  PubMed  Google Scholar 

Jiyan C, Li L, Gao X, et al. PCSK9 monoclonal antibody recaticimab in adult heterozygous familial hypercholesterolemia (REMAIN-3): a multicenter, randomized, double-blind, placebo-controlled phase 3 study [abstract no. 1068–09]. J Am Coll Cardiol. 2024;83(13, Suppl 2):1707.

Google Scholar